布地奈德福莫特罗辅助治疗老年中重度COPD稳定期的疗效及对患者肺功能的改善作用  

Efficacy of budesonide and formoterol in the adjuvant treatment of moderate and severe COPD in the elderly and the improvement of lung function

作　　者：宋玉亨 张庆龙 杨利娟[1] 李旭 王建伟 Song Yu-heng;Zhang Qing-long;Yang Li-juan;Li Xu;Wang Jian-wei(Department of Respiratory,Puyang People's Hospital Affiliated to Xinxiang Medical College,Puyang 457000,Henan,China)

机构地区：[1]新乡医学院附属濮阳市人民医院呼吸科,河南濮阳457000

出　　处：《四川生理科学杂志》2025年第2期288-290,465,共4页

摘　　要：目的:探讨老年中重度慢性阻塞性肺疾病(Chronic obstructive pulmonary disease,COPD)稳定期患者采用布地奈德福莫特罗辅助治疗的疗效及对患者肺功能的改善作用。方法:按照随机数字表法将院内2022年1月至2023年8月期间收治的老年中重度COPD稳定期患者180例分为参照组(n=90例)、试验组(n=90例),参照组患者进行异丙托溴铵治疗,试验组患者进行布地奈德福莫特罗辅助异丙托溴铵治疗,两组均治疗2 m。分析患者治疗有效率,治疗前后气道阻力指标(呼吸阻抗(Impedance,Zrs)、响应频率(Frequency response,Fres)),肺功能指标(用力肺活量(Forced vital capacity,FVC)、第1秒用力呼气容积(Forced expiratory volume second,FEV_(1))、深吸气量(Inspiratory capacity,IC)),血气指标(动脉血氧分压(Pressure of oxygen,PaO_(2))、氧合指数(Oxygenation index,OI))及炎症因子(白细胞介素-18(Interleukin-18,IL-18)、转化因子-β1(Transforming growth factor-β1,TGF-β1))水平。结果:试验组相较于参照组治疗总有效率更高(P<0.05)。两组患者治疗后Zrs、Fres相较于治疗前明显降低,试验组相较于参照组更低(P<0.05)。两组患者治疗后FVC、FEV_(1)、IC水平相较于治疗前明显升高,试验组相较于参照组更高(P<0.05)。两组患者治疗后PaO_(2)、OI水平相较于治疗前明显升高,试验组相较于参照组更高;IL-18、TGF-β1水平相较于治疗前明显降低,试验组相较于参照组更低(P<0.05)。结论:老年中重度COPD稳定期患者进行布地奈德福莫特罗辅助异丙托溴铵治疗可提升效果,降低气道阻力,改善肺功能,调节血气指标,使患者体内炎症降低。Objective:To investigate the effect of adjuvant treatment with budesonide and formoterol on pulmonary function in elderly patients with stable Chronic and severe obstructive pulmonary disease(COPD).Methods:According to random number table method,180 elderly patients with moderate to severe COPD in stable stage admitted to our hospital from 2022.01 to 2023.08 were divided into reference group(n=90 cases)and experimental group(n=90 cases).The reference group received ipratropium bromide treatment,and the experimental group received budesonide formoterol assisted ipratropium bromide treatment.Both the reference group and the experimental group were treated for 2 months.The treatment efficiency of the reference group and the experimental group was analyzed,airway resistance indexes(impedance(Zrs),frequency response(Fres)),pulmonary function(forced vital capacity(FVC),forced expiratory volume second(FEV_(1)),inspiratory capacity(IC)),blood gas index(arterial pressure of oxygen(PaO_(2)),oxygenation index(OI)),inflammatory factors(interleukin-18(IL-18),transforming growth factor-β1(TGF-β1))were analyzed.Results:The total effective rate of experimental group was higher than that of reference group(P<0.05).After treatment,Zrs and Fres in two groups were significantly lower than before treatment,and the experimental group was lower than the reference group(P<0.05).After treatment,the levels of FVC,FEV_(1) and IC in 2 groups were significantly higher than before treatment,and those in experimental group were higher than those in reference group(P<0.05).After treatment,PaO_(2) and OI levels in two groups were significantly higher than before treatment,and the experimental group was higher than the reference group.The levels of IL-18 and TGF-β1 were significantly decreased compared with those before treatment,and those in test group were lower than those in reference group(P<0.05).Conclusion:Treatment with budesonide formoterol subsidiary ipratropium bromide in elderly patients with stable moderate and severe COPD can impr

关 键 词：慢性阻塞性肺疾病 布地奈德福莫特罗 疗效 肺功能 

分 类 号：R563.9[医药卫生—呼吸系统]